CymaBay Therapeutics, Inc.
CymaBay Therapeutics, Inc. (CBAY) Revenue
Annual & quarterly revenue history · segment & region breakdown
CBAY · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsCymaBay Therapeutics, Inc. trailing twelve-month (TTM) revenue is $0.03B, an increase of 0.00% year-over-year from $0.03B in FY2023.
Revenue trend
2023 – 2012 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2023-12-31 | $0.03B | +$0.03B | — |
| 2022-12-31 | $0.00B | +$0.00B | — |
| 2021-12-31 | $0.00B | +$0.00B | — |
| 2020-12-31 | $0.00B | +$0.00B | — |
| 2019-12-31 | $0.00B | +$0.00B | — |
| 2018-12-31 | $0.00B | -$0.01B | -100.00% |
| 2017-12-31 | $0.01B | +$0.01B | — |
| 2016-12-31 | $0.00B | +$0.00B | — |
| 2015-12-31 | $0.00B | +$0.00B | — |
| 2014-12-31 | $0.00B | +$0.00B | — |
Compare revenue vs peers
BiotechnologyCompare CBAY revenue against listed peers. Click any row to open that company's revenue tab.
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income CymaBay Therapeutics, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
CymaBay Therapeutics, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from CymaBay Therapeutics, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
CBAY revenue · 4 questionsCBAY's trailing twelve-month (TTM) revenue is $0.03B. That is an increase of 0.00% year-over-year from $0.03B in FY2023.
▸ Source: FMP · CymaBay Therapeutics, Inc. SEC filings · GAAP · CymaBay Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026